ITCI vs. SYK

Last updated Apr 2, 2026

Compare and contrast key facts about Intra-Cellular Therapies, Inc. (ITCI) and Stryker Corporation (SYK).

Performance

ITCI vs. SYK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intra-Cellular Therapies, Inc. (ITCI) and Stryker Corporation (SYK). The values are adjusted to include any dividend payments, if applicable.

ITCI vs. SYK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ITCI Intra-Cellular Therapies, Inc.	0.00%	57.89%	16.62%	35.34%	1.11%	64.59%	-7.32%	201.23%	-21.34%	-4.04%
SYK Stryker Corporation	-6.03%	-1.48%	21.34%	23.80%	-7.42%	10.22%	18.17%	35.33%	2.43%	30.84%

Fundamentals

Total Revenue (TTM) ITCI : $680.64M SYK : $25.12B
Gross Profit (TTM) ITCI : $623.67M SYK : $15.91B
EBITDA (TTM) ITCI : -$116.21M SYK : $5.67B

Returns By Period

ITCI

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SYK

• 1D: 0.25%
• 1M: -14.66%
• YTD: -6.03%
• 6M: -9.07%
• 1Y: -10.91%
• 3Y*: 5.91%
• 5Y*: 7.38%
• 10Y*: 12.99%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ITCI vs. SYK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SYK

SYK Risk / Return Rank: 18
SYK Sharpe Ratio Rank: 19
SYK Sortino Ratio Rank: 18
SYK Omega Ratio Rank: 18
SYK Calmar Ratio Rank: 22
SYK Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ITCI vs. SYK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intra-Cellular Therapies, Inc. (ITCI) and Stryker Corporation (SYK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	ITCI	SYK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.48	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.31	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.50	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.57	—

Correlation

The correlation between ITCI and SYK is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ITCI vs. SYK - Dividend Comparison

ITCI has not paid dividends to shareholders, while SYK's dividend yield for the trailing twelve months is around 1.04%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ITCI Intra-Cellular Therapies, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SYK Stryker Corporation	1.04%	0.97%	0.90%	1.02%	1.16%	0.97%	0.96%	1.02%	1.23%	1.13%	1.31%	1.52%

Drawdowns

Drawdown Indicators

	ITCI	SYK	Difference
Max Drawdown Largest peak-to-trough decline	—	-58.63%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-18.80%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-31.68%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-43.80%	—
Current Drawdown Current decline from peak	—	-17.76%	—
Average Drawdown Average peak-to-trough decline	—	-13.07%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	8.18%	—

Volatility

Volatility by Period

	ITCI	SYK	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.46%	—
Volatility (6M) Calculated over the trailing 6-month period	—	15.63%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	22.58%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	23.74%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	26.06%	—

Financials